Chiropractors in Galax, VA Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Basic Essentials Spinal Care Center Chiropractor Medicare: Medicare Enrolled Practice Location: 2744 Glendale Rd, Galax, VA 24333 Phone: 276-236-3833 Fax: 276-236-9376 |
 Dr. Wade Edward Sproviero, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 2744 Glendale Rd, Galax, VA 24333 Phone: 276-236-3833 |
Dr. Todd Barton Fichtel, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 8268 Carrollton Pike, Galax, VA 24333 Phone: 276-236-4878 Fax: 276-238-9856 |
Todd Chiropractic, P.c. Chiropractor Medicare: Medicare Enrolled Practice Location: 8268 Carrollton Pike, Galax, VA 24333 Phone: 276-236-4878 Fax: 276-238-9856 |
News Archive
Drug reimportation emerges again in health debate
The Hill reports that Senate Majority Leader Harry Reid "has agreed to allow Sen. Byron Dorgan (D-N.D.) to bring an amendment to a vote this week that would allow the importation of cheaper prescription drugs from abroad despite the fact that it could blow up a truce between the White House, Senate Finance Committee Chairman Max Baucus (D-Mont.) and the Pharmaceutical Research and Manufacturers of America (PhRMA) on healthcare reform." Sen. Olympia Snowe (R-Maine) is among the amendment's co-sponsors.
Cathepsin B increases apoptosis in fulminant hepatic failure
The traditional view is that hepatocyte necrosis is the main feature of fulminant hepatic failure, but increasing evidence implicates a dominant role for hepatocyte apoptosis in this pathogenesis.
Enrollment complete in Exact Sciences DeeP-C screening trial for colorectal cancer
Exact Sciences Corp. today announced it has completed patient enrollment in its DeeP-C pivotal trial for colorectal cancer screening. The study enrolled more than 12,700 patients at sites in the United States and Canada.
Biogen's Multiple Sclerosis pill succeeds at a late phase clinical trial
Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries' Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.
New analysis of U.S. data provides insights into workplace sexual harassment
A new Gender, Work & Organization analysis of U.S. data from 1997-2016 provides new insights into workplace sexual harassment.
› Verified 5 days ago
Physical Therapists
Optometrists
Speech-Language Pathologists
Occupational Therapists
Chiropractors
Audiologists